GHK-Cu and skin studies
A copper-binding peptide with a long cosmetic history, small human studies, and important limits when the discussion turns to injections.
A copper-binding peptide
Glycine, histidine, and lysine form the three-part GHK chain. Amino acids are the building blocks of proteins. When GHK binds copper, the complex is called GHK-Cu. Copper Tripeptide-1 is the name commonly used in skin cosmetics. The free peptide and its copper-bound form need to be distinguished when interpreting a paper.
A review of skin regeneration studies describes GHK in human plasma, saliva, and urine. Its presence in the body helps explain the interest in its biology. That history does not establish that adding it to a cosmetic, or introducing it by another route, produces a particular benefit.
The main skin questions concern collagen, tissue remodeling, and visible appearance. Collagen is a protein that helps give skin strength. Remodeling describes the ongoing production and breakdown of the material around cells.
What the skin findings show
In a 1988 experiment with human fibroblasts, GHK-Cu increased collagen synthesis. Fibroblasts are cells that make connective tissue. This was a cell-culture finding: cells growing under laboratory conditions, rather than a trial measuring changes in people's faces.
The 2025 topical review discusses small studies reporting changes in firmness, elasticity, and fine lines. These findings support further study, while leaving uncertainty about the size and consistency of an effect across different preparations. The same review identifies delivery through intact skin as a practical limitation.
A cosmetic's ingredients, stability, and formulation matter to that question. Evidence about one preparation cannot be assumed to apply to every serum carrying a copper peptide name. A visible improvement also needs its own measurement; a laboratory change is not a direct measure of appearance.
Copper moving through skin
A 2011 experiment using excised human skin examined copper transport and retention after application as GHK-Cu over 48 hours. Excised skin is tissue studied outside the body. The investigators measured copper crossing skin preparations and copper remaining in the tissue.
The retained copper is sometimes described as a depot. That finding does not establish how long intact GHK-Cu remains in living skin. It also cannot establish how long a cosmetic improvement lasts. Transport, chemical identity, and appearance are separate endpoints, meaning separate outcomes that an experiment measures.
Hair findings
A six-month trial in 45 men with pattern hair loss tested a combination of GHK and 5-aminolevulinic acid. Hair-count gains were greater than with placebo. The result concerns that combination, in that population, during that period.
It cannot isolate the contribution of GHK or establish the effect of a different scalp serum. Nor does the trial answer whether gains persist after stopping. Reports of thicker-looking hair in community discussions are anecdotal, not clinical evidence, and add no controlled comparison to the trial.
Safety and route of use
People in skincare communities describe redness, itching, dryness, or stinging with topical copper peptides. These accounts are anecdotal, not clinical evidence. Small human studies offer limited reassurance about the preparations tested, but cannot reliably detect uncommon problems or establish long-term safety for every formulation.
Injections raise a different concern. The FDA's safety-risk page describes possible immune reactions related to peptide clumping and impurities, with limited human safety data. On that page, current as of April 22, 2026, injectable GHK-Cu is listed as nominated but withdrawn. Withdrawal is not clearance or approval.
The FDA's separate 503A list treats non-injectable GHK-Cu differently, placing it in Category 1 under evaluation. That conditional enforcement policy is not drug approval. No GHK-Cu medicine is FDA-approved, and a cosmetic history cannot settle the safety of systemic use.
What remains uncertain
The strongest human evidence discussed here concerns small topical studies. Broader claims about reversing aging extend beyond those findings. There is no established human pharmacokinetic basis for choosing an injection schedule; pharmacokinetics means how a substance moves through and leaves the body. This page provides no dosing instructions. The comparison separates the study endpoints, and the sources describe the evidence behind them.